Education
About Us
Working with TipRanks
Follow Us
Procept Biorobotics Corp. (PRCT)
:PRCT
PRCT Stock Chart & Stats
$31.68
-$0.85(-0.97%)
At close: 4:00 PM EST
$31.68
-$0.85(-0.97%)
Day’s Range― - ―
52-Week Range$27.80 - $99.60
Previous CloseN/A
Volume113.34K
Average Volume (3M)1.53M
Market Cap
$1.77B
Enterprise Value$1.77B
Total Cash (Recent Filing)$294.28M
Total Debt (Recent Filing)$78.93M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Mar 03, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding55,878,590
10 Day Avg. Volume1,400,150
30 Day Avg. Volume1,525,307
Financial Highlights & Ratios
PEG Ratio2.10
Price to Book (P/B)10.43
Price to Sales (P/S)18.70
P/FCF Ratio-40.50
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue5.91
Enterprise Value/Gross Profit9.16
Enterprise Value/Ebitda-23.43
Forecast
1Y Price Target
$54.57Price Target Upside72.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$326.42M
Bulls Say, Bears Say
Bulls Say
EarningsQ3 revenue totaled $83.3M, up 43% from last year and comfortably ahead of the Street's $80.8M forecast.
Growth StrategyPRCT highlighted an increased focus on driving utilization through the implementation of several organizational changes and launching several initiatives aimed at improving commercial execution.
LeadershipNew CEO Larry Wood views the current situation as an opportunity to improve utilization with better commercial onboarding strategies.
Bears Say
Operational ExecutionPRCT has to show improved operational execution for confidence in FY26 numbers to improve.
Sales GuidanceShares are trading off 6% after market due to lower-than-expected handpiece utilization and lowered handpiece guidance for 2025.
Utilization ConcernsUtilization needs to improve, as physicians are only averaging ~1-2 procedures per month, which needs to increase to drive sustained handpiece growth.
PROCEPT BioRobotics News
PRCT FAQ
What was Procept Biorobotics Corp.’s price range in the past 12 months?
Procept Biorobotics Corp. lowest stock price was $27.80 and its highest was $99.60 in the past 12 months.
What is Procept Biorobotics Corp.’s market cap?
Procept Biorobotics Corp.’s market cap is $1.77B.
When is Procept Biorobotics Corp.’s upcoming earnings report date?
Procept Biorobotics Corp.’s upcoming earnings report date is Mar 03, 2026 which is in 92 days.
How were Procept Biorobotics Corp.’s earnings last quarter?
Procept Biorobotics Corp. released its earnings results on Nov 04, 2025. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.412 by $0.032.
Is Procept Biorobotics Corp. overvalued?
According to Wall Street analysts Procept Biorobotics Corp.’s price is currently Undervalued.
Does Procept Biorobotics Corp. pay dividends?
Procept Biorobotics Corp. does not currently pay dividends.
What is Procept Biorobotics Corp.’s EPS estimate?
Procept Biorobotics Corp.’s EPS estimate is -0.32.
How many shares outstanding does Procept Biorobotics Corp. have?
Procept Biorobotics Corp. has 55,878,590 shares outstanding.
What happened to Procept Biorobotics Corp.’s price movement after its last earnings report?
Procept Biorobotics Corp. reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.412. Following the earnings report the stock price went down -9.737%.
Which hedge fund is a major shareholder of Procept Biorobotics Corp.?
Currently, no hedge funds are holding shares in PRCT
PROCEPT BioRobotics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$54.57 (72.25% Upside)
$54.57 (72.25% Upside)
Blogger Sentiment
Bullish
PRCT Sentiment 70%
Sector Average 68%
Sector Average 68%
Hedge Fund Trend
Decreased
By 7.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 6.2%
Last 30 Days ▼ 6.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.43%
12-Months-Change
Fundamentals
Return on Equity
-27.22%
Trailing 12-Months
Asset Growth
36.72%
Trailing 12-Months
Company Description
Procept Biorobotics Corp.
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
PRCT Company Deck
PRCT Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects strong revenue growth and significant increases in both U.S. and international sales, alongside positive gross margin expansion. However, persistent net losses, challenges in utilization growth, and anticipated procedural headwinds present concerns. The company remains optimistic about its strategic initiatives and long-term growth potential.View all PRCT earnings summariesPRCT Stock 12 Month Forecast
Average Price Target
$54.57
▲(72.25% Upside)
Technical Analysis
Alphatec Holdings
―
Artivion
―
LivaNova
―
Inspire Medical Systems
―
SS Innovations International
―
Ownership Overview
3.04% Insiders
38.92% Mutual Funds
31.73% Other Institutional Investors
11.13% Public Companies and Individual Investors